homefeedbacksupportlog on 19-Nov-2008 
  About F1000

 What is F1000 Biology?
 Key features
 How it's organized
 FAQs
 Faculties and sections
 Scope of sections
 List of Faculty Members
 The evaluation system
 Citing F1000
 Take a tour of the site
 Accessing fulltexts
 PubMed linkout
 How to subscribe
 Academic subscriptions
 Corporate subscriptions
 Try F1000 for free
 Who we are
 Media information
 Librarian resources
 Press releases
 In the press
 Developing countries
 F1000 Medicine
 Terms and conditions
 Privacy policy
 Contact us


Peter Kuhn
Department of Cell Biology, The Scripps Research Institute, La Jolla, United States of America

Faculty Member: Structural Biology > Structural Genomics [ since 13 November 2002 ]
[ Biography ] [ Homepage ] [ Evaluations ]
Biography

Current Position:
Associate Professor of Cell Biology, The Scripps Research Institute
Life Sciences Director and Visiting Scientist, Palo Alto Research Center, Scripps PARC

Previous Positions:
1999 - 2002 Assistant Professor, Stanford University, Stanford, CA, USA
1999 - 2002 Crystallography Group Leader, SSRL
1995 - 1999 Staff Scientist, Stanford University
1994 Visiting Scientist, New England Biolabs, Beverly, MA
1991 Visiting Research Student, Daimler Benz AG, Stuttgart, Germany

Education:
1995 Ph.D., Wadsworth Center, New York State Dept. of Health, and Physics Dept., State University of New York at Albany, NY
1993 M.Sc., Physics Dept., State University of New York at Albany, NY
1992 Vordiplom in Physics (B.Sc.), Julius Maximilians Universität Würzburg, Germany

Current Advisory Boards and Panels
since 2003: Member, Scientific Advisory Board and Consultant with significant financial interest, Lyncean Technologies Inc.
since 2002: Member, Resource Advisory Committee, National Resource for Automated Molecular Microscopy, TSRI.
since 2001: Member, Scientific Advisory Board, Alberta Synchrotron Institute, Canada
since 2001: Member, Scientific Advisory Board, NIH GM/CA-CAT, Argonne
since 2001: Member, Scientific Advisory Panel, NIH-NCRR BioCARS, Argonne

RESEARCH INTERESTS
*Developing novel therapeutics and diagnostics approaches with a focus on cancer and viral infections.
*Innovation and implementation of high-throughput biophysical and physical chemistry approaches in basic science and medicine.
*Proteomics and large scale biology discovery and technology programs using data centric experimentation approaches
*Innovative approaches to structural and functional genomics combining the tools and linking the experimental procedures of bioinformatics, molecular biology, structural biology and drug design

Home page

http://kuhn.scripps.edu

to email [Help]
Evaluations

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells.
Maheswaran S, Sequist LV, …, Toner M, Haber DA
N Engl J Med 2008 Jul 2 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Peter Kuhn with Dena Marrinucci
Evaluated 23 Jul 2008


Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Nagrath S, Sequist LV, …, Haber DA, Toner M
Nature 2007 Dec 20 450(7173):1235-9 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | William Seaman / Ulf Pettersson / Peter Kuhn / Surender Kharbanda
Evaluated 14 Jan 2008


Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.
Zhao C, Irie N, …, Suda T, Matsuo K
Cell Metab 2006 Aug 4(2):111-21 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Peter Kuhn / Nicola Partridge
Evaluated 30 Oct 2006

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
Fürstenberger G, von Moos R, …, Hamacher J, Boneberg EM
Br J Cancer 2006 Feb 27 94(4):524-31 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Peter Kuhn
Evaluated 28 Apr 2006

Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus.
Negrete OA, Wolf MC, …, Flick R, Lee B
PLoS Pathog 2006 Feb 2(2):e7 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Peter Kuhn
Evaluated 14 Feb 2006

EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus.
Negrete OA, Levroney EL, …, Tajyar S, Lee B
Nature 2005 Jul 21 436(7049):401-5 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Peter Kuhn
Evaluated 9 Dec 2005

Towards an understanding of radiation damage in cryocooled macromolecular crystals.
Nave C, Garman EF
J Synchrotron Radiat 2005 May 12(Pt 3):257-60 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Peter Kuhn
Evaluated 5 May 2005

EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity.
Koolpe M, Burgess R, Dail M, Pasquale EB
J Biol Chem 2005 Apr 29 280(17):17301-11 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Peter Kuhn / Robert Kelley
Evaluated 23 Mar 2005

Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling.
Himanen JP, Chumley MJ, …, Henkemeyer M, Nikolov DB
Nat Neurosci 2004 May 7(5):501-9 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Mark Bothwell / Harukazu Nakamura / Peter Kuhn
Evaluated 31 Aug 2004

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage.
Snijder EJ, Bredenbeek PJ, …, Spaan WJ, Gorbalenya AE
J Mol Biol 2003 Aug 29 331(5):991-1004 [abstract on PubMed] [related articles] [order article]
Selected by | Peter Kuhn
Evaluated 28 Aug 2003

^Top  Back to Faculty Members



© 1999-2008 Biology Reports Ltd unless otherwise stated. < info@f1000.com >   Terms and conditions   Legal info